The Food and Drug Administration said Tuesday that it approved Innoviva’s
INVA,
Xacduro pneumonia treatment, which fights the Acinetobacter bacteria.
The federal regulator said Xacduro, which treats ventilator-associated bacterial pneumonia and hospital-acquired bacterial pneumonia, is hard to treat and poses a great threat to human health.
The FDA granted approval of Xacduro, administered by intravenous infusion, to Entasis Therapeutics, acquired by the pharma company Innoviva last year.
